Tandem Diabetes Care, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)
Tandem Diabetes Care, Inc. (TNDM) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) of $690.00 thousand for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-05.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease · last filed 2021-05-05
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2021-03-31 was $690.00K, a 64.10% decline year-over-year.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2020-12-31 was -$2.82M, a 1347.35% decline year-over-year.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2020-09-30 was $3.65M.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2020-06-30 was $14.34M, a 3281.13% increase year-over-year.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2020 was $17.09M, a 54.28% increase from fiscal 2019.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2019 was $11.07M, a 83.34% decline from fiscal 2018.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2018 was $66.49M.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2017 was -$1.02M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 2 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 6 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 12 month |
|---|---|---|---|---|---|---|
| 2021-03-31 | $690.00K 10-Q · filed 2021-05-05 | -$2.13M derived: sum of 2 quarters · filed 2021-05-05 | $1.52M derived: sum of 3 quarters · filed 2021-05-05 | $15.86M derived: sum of 4 quarters · filed 2021-05-05 | ||
| 2020-12-31 | -$2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $829.00K derived: sum of 2 quarters · filed 2021-02-24 | $15.16M derived: sum of 3 quarters · filed 2021-02-24 | $17.09M 10-K · filed 2021-02-24 | ||
| 2020-09-30 | $3.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $17.98M derived: sum of 2 quarters · filed 2020-11-05 | $19.91M 10-Q · filed 2020-11-05 | $20.13M derived: sum of 4 quarters · filed 2021-05-05 | ||
| 2020-06-30 | $14.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $16.26M 10-Q · filed 2020-07-30 | $16.48M derived: sum of 3 quarters · filed 2021-05-05 | $14.16M derived: sum of 4 quarters · filed 2021-05-05 | ||
| 2020-03-31 | $1.92M 10-Q · filed 2021-05-05 | $2.15M derived: sum of 2 quarters · filed 2021-05-05 | -$173.00K derived: sum of 3 quarters · filed 2021-05-05 | $251.00K derived: sum of 4 quarters · filed 2021-05-05 | ||
| 2019-12-31 | $226.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | -$2.10M derived: sum of 2 quarters · filed 2021-02-24 | -$1.67M derived: sum of 3 quarters · filed 2021-02-24 | $11.07M 10-K · filed 2021-02-24 | ||
| 2019-09-30 | -$2.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$1.90M derived: sum of 2 quarters · filed 2020-11-05 | $10.85M 10-Q · filed 2020-11-05 | $8.30M derived: sum of 4 quarters · filed 2020-11-05 | ||
| 2019-06-30 | $424.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $13.17M 10-Q · filed 2020-07-30 | $10.62M derived: sum of 3 quarters · filed 2020-07-30 | $22.89M derived: sum of 4 quarters · filed 2020-07-30 | ||
| 2019-03-31 | $12.75M 10-Q · filed 2020-04-30 | $10.20M derived: sum of 2 quarters · filed 2020-04-30 | $22.46M derived: sum of 3 quarters · filed 2020-04-30 | $65.01M derived: sum of 4 quarters · filed 2020-04-30 | ||
| 2018-12-31 | -$2.55M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $9.72M derived: sum of 2 quarters · filed 2020-02-24 | $52.27M derived: sum of 3 quarters · filed 2020-02-24 | $66.49M 10-K · filed 2020-02-24 | ||
| 2018-09-30 | $12.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $54.81M derived: sum of 2 quarters · filed 2019-11-04 | $69.04M 10-Q · filed 2019-11-04 | |||
| 2018-06-30 | $42.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $56.78M 10-Q · filed 2019-08-01 | $56.78M 10-Q · filed 2018-07-30 | |||
| 2018-03-31 | $14.23M 10-Q · filed 2019-04-30 | |||||
| 2017-12-31 | -$1.02M 10-K · filed 2018-03-01 | -$1.02M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |